TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...
Zydus Lifesciences has launched Semaglutide Injection under the brand names SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided ...
Rising Chronic Disease Burden, Biosimilar Insulin Adoption, and Smart Connected Pen Technologies Drive Sustained Market Expansion.Austin, United States, March 12, 2026 (GLOBE NEWSWIRE) -- As per SNS ...
Zydus Lifesciences Limited (including its subsidiaries, hereafter referred to as “Zydus”), an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand names – ...